The aim of this work is to use Monte Carlo simulations and VOXEL phantoms to estimate the absorbed dose in paediatric patients (aged from 2 weeks to 16 y), with normal renal function, to whom technetium-99m-dimercaptosuccinic acid ( 99m Tc-DMSA) was administered, for diagnostic renal scintigraphy purposes; and compare them with values obtained using the International Commission on Radiological Protection (ICRP) methodology. In the ICRP methodology, the cumulated absorbed dose in the kidneys is estimated by multiplying the administered activity with the corresponding given dose coefficients. The other methods were based on Monte Carlo simulations performed on two paediatric voxel phantoms (CHILD and BABY), and another three phantoms, which were modified to suit the mass of the patients' kidneys, and other anatomical factors. Different S-values were estimated using this methodology, which together with solving the ICRP biokinetic model to determine the cumulated activities, allowed for the estimation of absorbed doses different from those obtained with the ICRP method, together with new dose coefficients. The obtained values were then compared. The deviations suggest that the S-values are strongly dependent on the patient's total body weight, which could be in contrast with the ICRP data, which is provided by age, regardless of other anatomical parameters.
INTRODUCTION
The growing use of ionising radiation in medicine has improved overall diagnosis and prognosis for many diseases. However, the population dose due to medical exposures has also increased significantly (1) , including in nuclear medicine procedures. This is particularly worrisome for paediatric patients (2) . In the USA, the total number of nuclear medicine procedures has increased almost 3-fold from 6.3 to 18.1 million procedures from 1984 to 2006, with approximately 1% of these being performed on children (3, 4) . According to a new UNSCEAR Committee report (5) , babies, children and adolescents are at a considerably higher risk of radiation-induced cancer than adults. The Committee reviewed 23 different types of cancer, and for about 25% of them (including leukaemia, thyroid, skin, breast and brain cancer) children were clearly more radiosensitive. In the case of solid tumours, for a fixed radiation dose, a 10-year-old person is at about twice the risk, and a newborn at about three times the risk, than a 40-year-old person (6) . In the more specific case of nuclear medicine, given the significant amount of examinations, and despite the fact that administered activities are low, it is necessary to properly quantify the potential risks associated with the use of radiopharmaceuticals, from a radiological protection viewpoint. In fact, a correct dosimetric assessment of radiopharmaceutical intake associated with a nuclear medicine procedure can significantly lead to the optimisation of the absorbed dose, improvement of the guidelines, and therefore, lead to minimising risk. Although there is no straightforward way to determine the 'actual' absorbed dose inside the human body, the formalism of the Medical Internal Radiation Dose (MIRD) Committee of the Society of Nuclear Medicine has been adopted as the International Commission on Radiological Protection (ICRP) calculation method for estimating radiation doses to organs from radionuclides distributed inside the body (7) . In the MIRD formalism, the time-integrated activity in each source region and the mean absorbed dose to the target organ per unit of nuclear transition are used to determine the absorbed dose to a target organ. The time-integrated activity may be obtained by solving biokinetic models.
Biokinetic data for a large number of radionuclides were published by the ICRP in ICRP Publication 53 (8) , and updated in the ICRP Publication 128 (9) . MIRD pamphlet 21 deals with the nomenclature standardisation between ICRP and MIRD (10) . However, despite this, and given the continuous advances in nuclear medicine, the biokinetic data, for many nuclear medicine procedures, more specifically in the case of children, can be and have been challenged. In fact, most of the research in this topic indicates that uncertainties are deemed very high (11) . Leggett et al. (12) argue that the uncertainties associated with biokinetic models are the largest sources of error in calculating the dose per unit of incorporated activity in nuclear medicine, not quantifying them. Further uncertainties are introduced by the anatomical differences between patients and the stylised models of the human body used for the determination of ICRP's internal organ dose coefficients up to now. Zankl et al. (13) report that, when comparing calculations using voxel phantoms with calculations using stylised ('MIRD-type') phantoms, deviations between 50 and 100% can be obtained. And finally, Hadid et al. (14, 15) and Parach et al. (16) reach similar conclusions, showing that when calculating dose coefficients with voxel phantoms and comparing them with a MIRD phantom, significant variations (up to few hundred percent) were obtained. Therefore, there is a considerable interest in investigating the radiation dose and its effects (17, 18) , in paediatric nuclear medicine patients. New dosimetric data in paediatric patients can be obtained with stateof-the-art techniques. Gathering a great collection of such data can then potentiate a better understanding of the biokinetics of different radiopharmaceuticals, and eventually lead to the optimisation of clinical protocols, and perhaps even contribute to reducing the dose to which paediatric patients are exposed, without affecting diagnostic outcomes.
This work aims at contributing to improve and complement such studies. The absorbed dose in 17 paediatric patients of different ages administered with technetium-99m-dimercaptosuccinic acid ( 99m Tc-DMSA), used in routine paediatric nuclear medicine for kidney disorder diagnostics, is estimated by means of biokinetic models and MC simulations using voxel phantoms. The obtained S-values were compared with values obtained from the available ICRP models and deviations were determined. Dose coefficients were also determined and compared with those available in the literature.
MATERIALS AND METHODS

Patient data
Seventeen paediatric patients with normal renal function were injected with a radiopharmaceutical containing 99m Tc-DMSA at the Hospital Garcia de Orta (HGO) in Almada, Portugal. Information about the patients can be found in Table 1 .
Biokinetic model
The activity curves as functions of time in the kidneys and other organs of interest were built using the available 99m Tc-DMSA biokinetic data from ICRP Publications 53 (8) and 128 (9) (The biokinetic data from ICRP Publications 53 and 128 will be referred as ICRP model from now on. The models in Publications 53 and 128 are identical) and ICRP Publication 106 (19) . Assuming immediate uptake of the administered activity A 0 , the activity as a function of time A S (t), in the source organ S, with an effective half-life T i,eff , can be expressed as
where F S is the fraction of the administered radiopharmaceutical incorporated by the organ S; a i is the fraction of F S eliminated with a biological halflife T i ; and n is the number of elimination components. The effective half-life, T i,eff , is given by Equation 2 , where T i and T p are the biological and physical half-life, respectively (18) .
The cumulated activity, Ã S , is given by Equation 3 , which is the quantity that is used to determine the absorbed dose, by making use of the ICRP dose coefficients.
The ICRP biokinetic model states that, after 99m Tc-DMSA is intravenously injected on a subject, it is distributed in the extracellular fluid. Once inside the extracellular fluid, half is deposited in the renal cortex (hence F s = 0.5 in the kidneys), where it is retained for a long period of time. Also, and as shown in Table 2 , a further fraction is temporarily retained in the liver and spleen. Hereupon, when referring to the ICRP model, a fraction of 0.5 is taken up in the renal cortex, with an uptake halftime of 1 h, and it is assumed to be retained permanently. Fractions of 0.1 and 0.01 are taken up in the liver and spleen with a half-time of 1 h and cleared with half-times of 2 h (0.5) and 1.8 d (0.5). This radiopharmaceutical is excreted exclusively via the kidneys, which makes them an important source region for the radiation dosimetry of this substance. The biokinetic model is constructed for adults, and it is possible that physiological and biokinetic values are different in children and adolescents, however this is beyond the scope of this work, which intends to look at dosimetric data. Finally, it should be noted that, in this study, no blood data was taken.
Monte Carlo simulations
Software and paediatric voxel phantoms
The simulations were performed using the stateof-art MCNPX 2.7.0 computer program developed by the Los Alamos National Laboratory (LANL) (20) and two paediatric voxel phantoms BABY (8 weeks) and CHILD (7 y) that are shown in Figure 1 . These phantoms were developed at the Helmholtz Zentrum München-German Research Center for Environmental Health (HMGU) (21) . Table 3 reports the main features of these two phantoms.
Considering the large variability of the patients (weight and age), in order to obtain more accurate results, the voxel dimensions of the phantoms (BABY and CHILD) were modified to fit the anatomy of the patients more accurately. Therefore, besides the aforementioned BABY and CHILD phantoms, another four voxel phantoms (Baby_9.5 kg, Child_13.2 kg, Child_21.5 kg and Child_30 kg) were created by scaling the voxels of the two original phantoms. The ICRP anatomical information to create these new voxel phantoms, that is, the body height and kidney mass for 1-, 5-, 10-and 15-year-old children, was taken from ICRP Publication 89 (20) . The parameters by which the new voxel phantoms were scaled were:
(a) The ICRP kidney mass from ICRP 89, by knowing the number of voxels that correspond to the two kidneys, and knowing that the kidney density does not change, a new volume can be determined for a different mass by simple proportionality. (b) The body height values. The z dimension of the voxels was scaled so the condition for the new volume determined in item (a) could be satisfied.
Subsequently, the x-and y-dimensions were scaled accordingly, preserving the proportionality of item (a). The rest of the anatomical data can then be estimated from this. Although this is a practical method to match the kidney mass and the height to the ICRP value, there are still significant deviations in the masses of the other organs and the scaling of the phantoms introduces another source of uncertainty, as the distances between organs' centres of mass will also vary, and this can have influence in the cross-fire S-values. For instance the chord length (defined as the distance between the organs' centres of mass) between the liver and the right kidney varies in the CHILD phantom, as it is scaled, from 5.84 cm to 7.68 cm. However, since, in the case of this study, the main influence in the absorbed dose will be the self-absorption S-value, the geometric variations will have a minor impact, and it is beyond the scope of this work to determine their influence.
Although the weight of patient 1 is closer to that of a newborn, the ICRP dose conversion coefficient for the 1 year old had to be used, since ICRP does not provide dose coefficients for newborns.
The new voxel phantoms were named according to their weight: A depiction of the VOXEL phantoms obtained with this method is shown in Figure 2 . Table 4 shows the organ masses for the ICRP kidneys, liver and spleen, total height, from ICRP 89 and from the voxel phantoms and the respective deviations (%), and ratios, between them.
As can be seen in Table 4 , there are significant variations between the liver and spleen mass for the five phantoms relative to the ICRP 89 values.
For Baby_9.5 kg, the liver and spleen are larger than the ICRP values. For Child_21.5 kg and Child_30 kg the spleen is significantly larger than ICRP, while the liver is smaller. It is also important to notice that the full body weight of the voxel phantoms is always smaller than the ICRP values, decreasing with age, leading to almost half the weight value than the body weights of the patients within the age range of 15 y. In this case, the adult GSF voxel phantom (15) could have been scaled to match the kidney mass and the height of the 15-year-old child, but this would be beyond the scope of this work (which is to use child voxel phantoms to estimate absorbed dose). Also, it would have led to values with no significant variation to absorbed dose determined with ICRP since that is, overall, the ICRP methodology (scaling adult voxel phantoms to fit the anatomical parameters of children of different ages). In fact, in the age-specific MIRDtype phantoms (Cristy and Eckerman (22) ), considerations on human anatomical growth with age have been taken into account, but these differences will be very small for the 15-year-old child. It should be noted, however, that in this study a voxel phantom of a 7-year-old child is used to determine the S-values for 15-year-old children.
In order to determine the dose and other parameters, each patient was ascribed with one of the voxel phantoms, which was its closest ICRP match (defined as age) or by total weight (23) . In cases where the closest matches by weight, and by age, were different, both phantoms were used for absorbed dose calculations, and the resulting values were compared with ICRP values, as shown in Table 5 .
S-value estimations using MC simulations 99m Tc sources were simulated separately in the kidneys, liver, spleen and total body of the paediatric voxel phantoms. Photons and betas were considered as emitted particles (24) . In order to have low statistical errors (1σ < 3%), 10 9 particles were simulated. Tally F6 (deposited energy per mass in a cell per emitted particle of the source in MeV/g) was used to obtain the absorbed dose in the kidneys. One can clearly see that this is, in fact, in the MIRD formalism, the same as determining the S-value. Multiplying this S-value for each phantom ascribed to a patient by the cumulated activity values, the absorbed dose in the kidneys can be determined, using the phantom closest to the patient both by total body weight or by age (method 1 or method 2).
The kidney mass and the distances between the kidneys and the various source organs, that is, the anatomy of the phantom, will have an impact in the energy deposited in the kidneys MC simulations. In fact, the distance between source and target region is a parameter that influences the specific absorbed fractions in internal dosimetry (25) , which is not taken into account in this study. 
RESULTS AND DISCUSSION
Biokinetic model activity curves
The ICRP model (8, 9) is used to build the activity curves as a function of time for each source region, following Equation 1. The administered activity A 0 is decided at the Nuclear Medicine Service of HGO, according to protocol and adopted guidelines (26) . Figure 3 shows the percentage activity per injected activity curves for all affected organs.
Also, for each patient the cumulated activity (Ã) is determined (estimated by the biokinetic model from ICRP 128 through Equation 3), which is shown in Table 6 .
These values can be used to estimate the absorbed dose, by multiplying them with either the ICRP dose coefficients or, alternatively, the values estimated using MC simulations, using methods 1,2 or 3.
Monte Carlo results and absorbed dose estimation Table 7 shows the Monte Carlo estimations of the S-values for the kidneys when a source of 99m Tc is simulated in different organs, for the five used Table 6 . Cumulated activities in all important organs and regions, using the biokinetic model from ICRP Publication 53.
Patient
Kidneys ( where S 0 in units of mGy/MBq is the theoretical S-value where the total body mass m≪k, and k is a 'mass constant' with units of kg
, the S-values for the real weight of the patient can be computed and used to determine the absorbed dose. This will be called method 3. The obtained functions are shown in Figure 4 .
The S-values for each organ obtained in this way, take into account the real value of the patient's body, and giving a more direct correlation to weight, are presented in Table 8 .
The ICRP model predicts values for the absorbed dose, by multiplying the administered activity of each patient (A 0 ) by the corresponding dose coefficients available on ICRP Publication 80 (the ICRP Publication 80 is an addendum to ICRP Publication 53) (27) , obtaining a dose value called D ICRP in this work. This is called the ICRP method in this study, and will be considered the reference to which the other methods will be compared.
The other methods are: Table 9 .
Given that the Child_21.7 kg (the original CHILD phantom) and the Child_21.5 kg phantoms provide very similar S-values, resulting in deviations in absorbed dose estimation that is less than~5%, the Child_21.7 kg phantom was not used altogether, and the Child_21.5 kg used instead, although the Child_21.7 kg was used for the calculations of the 6.97 × 10 Using fitted S-factors to patient's weight fitting exponential. The obtained results can be summarised as follows:
(a) For Group 1 (patient 1), as shown in Figure 5a , the method to which deviations to the ICRP values are minimal (−7.8%) is method D 1 , using Baby_9.5 kg. Method D 2 would have used the Baby_4.3 kg, which leads to an absorbed dose value that deviates from the ICRP by~97%. The difference in mass is very significant. Given that this patient's mass is 3.4 kg, this would in fact mean that realistically, in terms of weight, the Baby_4.3 kg phantom is more suited for dose calculations, as is shown by the use of method D 3 , which fits the S-values to the real weight of the patient and estimates a dose much closer to that of method D 2 . This in turn means that if one used the ICRP method the dose would have been underestimated by a factor of 50%. Finally it should be noted, again, that ICRP does not provide dose conversion coefficient data for newborns. (b) For Group 2 (patients 2-10), as shown in Figure 5b, . This is again due to the fact that the phenomenological equation is inadequate to estimate doses for patients with a total body weight higher than 30 kg.
Estimation of dose coefficients to the kidney
The dose coefficients are established for the organs involved in the biodistribution of radiopharmaceuticals, and are based on the MIRD system (28) . These coefficients represent absorbed dose per unit of administered activity (mGy/MBq), and are used clinically for absorbed dose estimation to the organs, in this case, to the kidney. Based on the different methods used to estimate absorbed doses besides the ICRP 80 in this study, new dose coefficients have been computed for the kidneys and compared with those from the ICRP model, as shown in Table 10 . Figure 6 shows the dose coefficients variation with the different methodologies. The four different methods do not yield significant variations, with the notable exception of method 3, which gives dose conversion coefficient values that are much smaller for the groups of patients 13-14 and 15-17. This method is inadequate to estimate dose in this case, as no voxel phantom used in this study has a body weight higher than 30 kg, and all the aforementioned patients have a total body weight far exceeding this value.
CONCLUSIONS
Absorbed dose in the kidneys of 17 paediatric patients undergoing renal scintigraphies was estimated by means of biokinetic models, and dose coefficients from reference ICRP data (method ICRP). The absorbed dose was also assessed by calculating the individual S-values in the kidneys using MC simulations, using two possible alternative voxel phantoms (methods 1 and 2) and finally by fitting the previously MC obtained S-values as a function of the patients' body weight to a phenomenological function used for the purpose (method 3). This allowed for the estimation of dose coefficients using four different methodologies and to a comparison of these values.
MC simulations can be used to compute the dose coefficients, and provide a complementary methodology to be compared with the established ICRP models. By scaling the two available voxel phantoms with specific ages (2 months and 7 y) to match the ICRP values for kidney mass and height for 1 year, 5 year, 10 year and 15 year olds, by changing voxel volumes, a valid comparison to the ICRP values is possible.
As the dose to the kidney in the case of renal scintigraphies using 99m-TC-DMSA is mostly due to selfirradiation (where the beta particles play an important part) as well as irradiation from the rest of the body (the liver and the spleen account for a very low percentage of the total dose to the kidney), the kidney mass of the used phantoms will play a strong role in the dose assessment. This is visible in the different results, obtained for each group, as the kidney size and mass change in the phantoms used for the calculations, suggesting that a more convenient parameter for providing ICRP values is mass, rather than age. ICRP seems to have followed a similar approach used in pharmacokinetics to determine the correct dosage to paediatric patients from drugs, by age, although this seems to be an open issue, as the weight-age variation is not linear (29) . Also, the given values in the models tend to be the average for a 'typical' child or baby with a specific age, when in clinical practice there can be huge disparities between the patient's characteristics and those of the models (as can be noticed in this study).
Because of this, the dose coefficients established by ICRP can be either underestimating the absorbed dose (such as in the case of patient 1, where the body weight is closer to the value provided to a newborn), or overestimating it, such as in the case of patients [13] [14] [15] [16] [17] , where the body mass of the patients far exceeds the body weight of the voxel phantoms, although it is close to the ICRP data provided for 10 and 15 years olds. In fact the voxel phantoms used in this study do not have the same body weight as the ICRP phantoms, for any age, and the weight difference between the total body weight of the used voxel phantoms and the ICRP values increases with age, being higher for 10 and 15 years old.
Since it is contra-indicated to expect a clinical implementation of CT scans to construct individual voxel phantoms of each patient, the most accurate methodology would perhaps be to build a variety of phantoms at different ages and adjust them only within a much smaller weight and height variety. With this, one could construct S-value curves for different anatomical parameters (age, height and girth). Clinicians and medical physicists could estimate a more accurate value of dose by correlating one of these phantoms with their patient. Perhaps they can even test two different values (if the values for the patients are closer in mass to one but in height to the other and vice-versa) and obtain two different values of dose, which could give them an idea of the uncertainty of their estimation. This could clearly lead to dose optimisation, which is a fundamental pillar of radiation protection. This is especially valid for paediatric patients as they are known to be more radiosensitive than adults. It is not unfair to assume that such methods are within practical reach of clinicians/medical physicists, or other workers.
